GlassScriptPhysician profile
Micah W Rothstein
NPI 1104902683
$5,240.94
in general payments reported to CMS, 2019-2025
32 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $675 · 2021: $1,113 · 2022: $569 · 2023: $766 · 2024: $678 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.30 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,014.48 | 2019-2025 | Clareon, Rocklatan, Argos |
| Allergan, INC. | $877.65 | 2019-2022 | |
| Abbvie INC. | $707.05 | 2022-2025 | Durysta, Ozurdex, Xen Glaucoma Treatment System |
| Aerie Pharmaceuticals, INC. | $492.10 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $217.90 | 2022-2025 | Xiidra, Envista Envy Iol, Vyzulta |
| Sight Sciences, INC. | $191.81 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $183.25 | 2019-2024 | Eylea Hd, Eylea |
| Omeros Corporation | $177.51 | 2019-2021 | |
| Glaukos Corporation | $174.13 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idose, Idosetr |
| Harrow Eye, LLC | $121.93 | 2025 | Vevye |
| Eyepoint US, INC. | $116.23 | 2021 | |
| Rxsight INC | $113.08 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Beaver-Visitec International, INC. | $101.59 | 2019 | |
| Apellis Pharmaceuticals, INC. | $100.29 | 2023-2024 | Syfovre |
| Mallinckrodt Hospital Products INC. | $96.71 | 2025 | Acthar |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $69.65 | 2020 | |
| New World Medical,INC. | $55.84 | 2022 | |
| Rayner Intraocular Lenses Limited | $52.64 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Tearlab Corp | $49.24 | 2023 | Tearlab Osmolarity System |
| Ivantis, INC | $45.92 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $42.25 | 2021 | |
| Iridex Corporation | $37.57 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.87 | 2020-2021 | |
| Amgen INC. | $27.24 | 2024 | Tepezza |
| Nova Eye, INC. | $22.84 | 2024 | |
| Sun Pharmaceutical Industries INC. | $21.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.41 | 2020 | |
| Biogen, INC. | $20.08 | 2024 | Byooviz |
| Horizon Therapeutics Plc | $18.54 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $14.34 | 2025 | Xdemvy |
| Akorn, INC. | $11.95 | 2020 | |
| Eyevance Pharmaceuticals LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Rothstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.